HOME >> MEDICINE >> NEWS
Tamoxifen for prevention of breast cancer encouraging results but risks still unclear

Early findings from a randomised trial investigating the effectiveness of tamoxifen to prevent breast cancer are reported in this week's issue of THE LANCET. Although tamoxifen reduced breast cancer incidence by a third compared with women given placebo, the authors of the study caution that it is still too early to fully assess the risk to benefit ratio of tamoxifen as a preventative strategy for breast cancer.

Tamoxifen is well known in its effect to decrease recurrence of (and death from) breast cancer; however, three clinical trials on the use of tamoxifen to prevent breast cancer have reported mixed results. The overall evidence supports a reduction in the risk of breast cancer, but whether this benefit outweighs the risks and side-effects associated with tamoxifen is unclear.

Jack Cuzick from Cancer Research UK, lead investigator of the International Breast Cancer Intervention Study (IBIS-I) and colleagues undertook a double-blind placebo-controlled randomised trial of tamoxifen, 20 mg/day for 5 years, in around 7000 women from the UK, Europe, Australia and New Zealand who were aged 3570 years and who were at an increased risk of breast cancer (eg. They had a Family history of the disease or had a benign lesion associated with an increased risk of breast cancer).

The frequency of breast cancer was reduced by a third among Women given tamoxifen (69 breast cancers in 3578 women in the tamoxifen group and 101 breast cancers in 3566 in the placebo group). Endometrial cancer--considered to be increased by tamoxifen use--was doubled in the tamoxifen group (11 instances compared with 5 in the control group), but this increase was not statistically significant, and all cases were localised (stage 1) and curable by hysterectomy.

However, tamoxifen use was associated with more than a doubling in the risk of blood-clotting complications, especially after surgery or long periods of immobilisation. The investigators comment that the incre
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
12-Sep-2002


Page: 1 2

Related medicine news :

1. Tamoxifens risks similar in African American and white women
2. Tamoxifen and estrogen have similar effects on the brain
3. Tamoxifen found to increase risk of endometrial cancer
4. Views Of Tamoxifen And Synthetic Estrogen In Action Provide Clues For Designing Better Drugs
5. International breast cancer prevention study launches in the United States and Canada
6. Cavity prevention tips for pre-school age children
7. HIV and ID doctors oppose ideologically driven STI prevention policies
8. School-based smoking prevention programs ineffective
9. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
10. Mount Sinai stroke prevention trial published in JAMA
11. New stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding

Post Your Comments:
(Date:9/3/2015)... ... September 03, 2015 , ... E-Volve Health, ... leading national healthcare solutions organization, to provide electronic medical record (EMR) consulting services ... Amerinet members will receive negotiated pricing on E-Volve Health’s Epic EMR consulting, custom ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mayo ... Indianapolis, have chosen Center for Hospice Care (CHC) for physician Hospice and ... at CHC as part of fulfilling their requirements for obtaining national Board Certification ...
(Date:9/3/2015)... ... 2015 , ... DriButts, a non-profit organization dedicated to helping ... Group to manufacture a long-lasting reusable diaper for warm weather climates where there ... 600 DriButts Diapers to rural areas of Haiti during a trip scheduled for ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a ... Healthcare Research and Policy Analysis has found physician leadership development training programs to ... percent of respondents said their organizations conduct some kind of physician leadership development ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... care community to be situated at 4400 Columbine Drive in Bellingham, Washington. Silverado ... 2016, and has been carefully designed to serve up to 80 people living ...
Breaking Medicine News(10 mins):Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:Site Dedication Ceremony to Celebrate New Silverado Memory Care Community 2
(Date:9/3/2015)... 2015 Research and ... of the "Global Craniomaxillofacial (CMF) Devices Market ... The global craniomaxillofacial devices market to grow at ... report covers the present and future scenario of ... calculate the market size, we use revenues generated ...
(Date:9/3/2015)... , Sept. 3, 2015 HeartWare International, ... of less invasive, miniaturized circulatory support technologies that are ... that its President and Chief Executive Officer, Doug ... Wells Fargo Healthcare Conference at 8:50 a.m. ET on ... 9-10, 2015 at The Hyatt Regency, Boston ...
(Date:9/3/2015)... Sept. 3, 2015 Research and Markets ( ... "Investigation Report on China Olmesartan Market, 2010-2019" report ... medoxomil was successfully developed by Sankyo Pharmaceuticals Co., Ltd ... olmesartan medoxomil was approved by FDA to enter the ... best- selling drug in the world after it succeeded ...
Breaking Medicine Technology:Global Craniomaxillofacial (CMF) Devices Market 2015-2019 - Product Innovation and Cost Reduction a Key Market Trend 2HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast 2China Olmesartan Investigation Market Report 2010-2019 2
Cached News: